Ackman: Valeant A "Good" Roll Up Firm, Strategy SynergiesMark Melin
Bill Ackman was defending Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) today, upon which he is dependent on for a high stock price to fuel his hedge fund’s involvement in the Valeant / Allergan acquisition. The deal to purchase Allergan, Inc. (NYSE:AGN) is based in large part on the price of Valeant shares. In an interview with CNBC today, Ackman also talked about Valeant in terms of its value as a “roll up” company.
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat